Jeong-Gun Park

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Robert P. Giugliano, Terje R. Pedersen, Jeong-Gun Park et al. · The Lancet · 2017 · 658 citations

Cardiovascular Disease, Pcsk9 Inhibitor Evolocumab, Pharmacology +9

Epidemiology of Shock in Contemporary Cardiac Intensive Care Units

David D. Berg, Erin A. Bohula, Sean van Diepen et al. · Circulation Cardiovascular Quality and Outcomes · 2019 · 393 citations · Full text

Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects

Nimalie D. Stone, Shelia B. Dunaway, Charles Flexner et al. · Antimicrobial Agents and Chemotherapy · 2007 · 119 citations · Full text

Contraceptive Efficacy of Oral and Transdermal Hormones When Co-Administered With Protease Inhibitors in HIV-1-Infected Women: Pharmacokinetic Results of ACTG Trial A5188

Mary Vogler, Kristine B. Patterson, Lori Kamemoto et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 115 citations · Full text

Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry

David D. Berg, Christopher F. Barnett, Benjamin B. Kenigsberg et al. · Circulation Heart Failure · 2019 · 94 citations · Full text